ĐÁNH GIÁ HIỆU BÀI THUỐC SÂM TÔ ẨM ĐIỀU TRỊ NGƯỜI BỆNH NHIỄM COVID-19 MỨC ĐỘ NHẸ: MỘT NGHIÊN CỨU ĐOÀN HỆ TIẾN CỨU

Abstract

Objectives: The study evaluated the effectiveness of improving prognosis in patients with mild COVID-19 by comparing the rate of exacerbation and mortality between the group taking Shensuyin decoction plus standard treatment with the group taking standard treatment only. Method: Prospective cohort study with 2 groups including the exposed group (oral Shensuyin decoction plus standard of care, SSY+SOC, N=210) and the unexposed group (standard of care, SOC, N= 210). In the exposed group, patients received 1 dose of Shensuyin decoction per day (divided into 2 oral times per day) for 7 consecutive days. Exacerbation rates and mortality were monitored continuously for 14 days or until recovery for critically ill patients. Results: The exacerbation rate in the SSY+SOC group of 3.33% was significantly lower than that in the SOC group of 11.90% with RR = 0.28 (95% CI, 0.12 – 0.63), the difference between very statistically significant with p<0.001. No deaths were recorded in the two groups. Conclusion: Combining Shensuyin decoction with standard of care improves the prognosis of patients with mild COVID-19.